Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study

被引:84
作者
Shin, Ju-Young [1 ,2 ,3 ,4 ]
Roughead, Elizabeth E. [5 ]
Park, Byung-Joo [6 ]
Pratt, Nicole L. [5 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Res Inst, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada
[3] McGill Univ, Dept Biostat, Montreal, PQ, Canada
[4] McGill Univ, Dept Occupat Hlth, Montreal, PQ, Canada
[5] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
[6] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea
来源
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 353卷
基金
澳大利亚国家健康与医学研究理事会;
关键词
NERVOUS-SYSTEM STIMULANTS; AMBULATORY BLOOD-PRESSURE; RISK; EVENTS; ADOLESCENTS; MEDICATIONS; DESIGNS; DRUGS; DEATH;
D O I
10.1136/bmj.i2550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. DESIGN Self controlled case series analysis. SETTING Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. PARTICIPANTS 1224 patients aged <= 17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. MAIN OUTCOME MEASURES A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. RESULTS Increased risk of arrhythmia was observed in all exposed time periods-that is, periods of treatment with methylphenidate-(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. CONCLUSION The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder
    Upadhyaya, Himanshu
    Kratochvil, Christopher
    Ghuman, Jaswinder
    Camporeale, Angelo
    Lipsius, Sarah
    D'Souza, Deborah
    Tanaka, Yoko
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2015, 25 (10) : 799 - 809
  • [22] Methylphenidate Improves Autonomic Functioning among Youth with Attention-Deficit/Hyperactivity Disorder
    Morris, Stephanie S. J.
    Musser, Erica D.
    Tenenbaum, Rachel B.
    Ward, Anthony R.
    Raiker, Joseph S.
    Coles, Erika K.
    RESEARCH ON CHILD AND ADOLESCENT PSYCHOPATHOLOGY, 2022, 50 (05): : 591 - 603
  • [23] Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder
    Wigal, Sharon B.
    Childress, Ann
    Berry, Sally A.
    Belden, Heidi
    Walters, Faith
    Chappell, Phillip
    Sherman, Nancy
    Orazem, John
    Palumbo, Donna
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2017, 27 (08) : 690 - 699
  • [24] Effects of Methylphenidate on Acute Math Performance in Children With Attention-Deficit Hyperactivity Disorder
    Grizenko, Natalie
    Cal, Emmy
    Jolicoeur, Claude
    Ter-Stepanian, Mariam
    Joober, Ridha
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2013, 58 (11): : 632 - 639
  • [25] Sexually Transmitted Infection Among Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder: A Nationwide Longitudinal Study
    Chen, Mu-Hong
    Hsu, Ju-Wei
    Huang, Kai-Lin
    Bai, Ya-Mei
    Ko, Nai-Ying
    Su, Tung-Ping
    Li, Cheng-Ta
    Lin, Wei-Chen
    Tsai, Shih-Jen
    Pan, Tai-Long
    Chang, Wen-Han
    Chen, Tzeng-Ji
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (01) : 48 - 53
  • [26] Incidence and risk of attention-deficit hyperactivity disorder in children with amblyopia: A nationwide cohort study
    Su, Chien-Chia
    Tsai, Chia-Ying
    Tsai, Tzu-Hsun
    Tsai, I-Ju
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2019, 47 (02) : 259 - 264
  • [27] Cognitive switching processes in young people with attention-deficit/hyperactivity disorder
    Oades, Robert D.
    Christiansen, Hanna
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2008, 23 (01) : 21 - 32
  • [28] A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder
    Kollins, Scott H.
    Braeckman, Rene
    Guenther, Sven
    Barrett, Andrew C.
    Mickle, Travis C.
    Oh, Charles
    Marraffino, Andrea
    Cutler, Andrew J.
    Brams, Matthew N.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2021, 31 (09) : 597 - 609
  • [29] Cardiovascular Safety of Medication Treatments for 198 Attention-Deficit/Hyperactivity Disorder
    Newcorn, Jeffrey H.
    Donnelly, Craig
    MOUNT SINAI JOURNAL OF MEDICINE, 2009, 76 (02): : 198 - 203
  • [30] Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome
    Roche, M.
    Mircher, C.
    Toulas, J.
    Prioux, E.
    Conte, M.
    Ravel, A.
    Falquero, S.
    Labidi, A.
    Stora, S.
    Durand, S.
    Megarbane, A.
    Cieuta-Walti, C.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (08) : 795 - 800